Alopecia Tied to Higher Prevalence of Autoimmune, Psychiatric Comorbidities
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Aug. 6, 2024 -- Patients with alopecia areata (AA) have a higher prevalence of autoimmune and psychiatric comorbidities at time of diagnosis as well as a higher risk for new-onset autoimmune and psychiatric comorbidities after diagnosis, according to a study published online July 31 in JAMA Dermatology.
Arash Mostaghimi, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues examined risks for developing new-onset psychiatric or autoimmune diseases after diagnosis of AA. The analysis included data from 16,512 patients with AA and 66,048 without AA (ages, 12 to 64 years).
The researchers found that overall, patients with AA had a higher prevalence of psychiatric (30.9 versus 26.8 percent) and autoimmune (16.1 versus 8.9 percent) comorbidities at AA diagnosis. Incidence was also higher in patients with AA without a history of these comorbidities compared with matched controls. Patients with AA had a significantly higher risk for developing a psychiatric (adjusted hazard ratio, 1.3) or autoimmune (adjusted hazard ratio, 2.7) comorbidity compared with controls.
"These data highlight the most common comorbidities among patients with AA and may help physicians counsel and monitor patients newly diagnosed with AA," the authors write.
Several authors disclosed ties to pharmaceutical companies, including AbbVie, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-07 07:15
Read more
- Female Pediatricians Earn About 93 Percent of Male Pediatricians
- Quitting Smoking After Cancer Diagnosis Boosts Survival by Up to 26%
- Mindfulness Meditation Could Have Direct Effect in Reducing Pain
- ASA: Risk for Postoperative Delirium Increased With Poor and Worsening Sleep
- Ordinal Score Predicts Freedom From Epilepsy One Year After Surgery
- Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions